123 Results

People

  1. Motzer
    Motzer
  2. Saltz
    Saltz
  3. Dickler
    Dickler
  4. Jaimes
    Jaimes
  5. Glezerman
    Glezerman
  6. Miller
    Miller
  7. Aghajanian
    Aghajanian
  8. Flombaum
    Flombaum
  9. Hudis
    Hudis
  10. Lichtman
    Lichtman

Groups

  1. Department of Medicine (82)
  2. Solid Tumor Oncology Division (63)
  3. Genitourinary Oncology Service (23)
  4. Division of Subspecialty Medicine (17)
  5. Renal (16)
  6. Gastrointestinal Oncology Service (15)
  7. Gynecologic Medicine Service (13)
  8. Center for Hematologic Malignancies (12)
  9. Hematologic Malignancies, Division of (12)
  10. Survivorship Research (12)
  1. "proteinuria"
Formats
  1. Journal Article (116)
  2. Review (3)
  3. Book Section (2)
  4. Research Letter (2)
Groups
  1. Department of Medicine (82)
  2. Solid Tumor Oncology Division (63)
  3. Genitourinary Oncology Service (23)
  4. Division of Subspecialty Medicine (17)
  5. Renal (16)
  6. Gastrointestinal Oncology Service (15)

More Groups

People
  1. Robert Motzer (19)
  2. Leonard Saltz (8)
  3. Ilya Glezerman (7)
  4. Edgar Jaimes (6)
  5. Maura Dickler (6)
  6. Vincent Miller (5)

More People

Years
  1. 2025 (3)
  2. 2024 (9)
  3. 2023 (5)
  4. 2022 (2)
  5. 2021 (3)
  6. 2020 (8)

More Years

Publications
  1. Journal of Clinical Oncology (11)
  2. Clinical Cancer Research (5)
  3. Lancet Oncology (5)
  4. The Oncologist (4)
  5. Annals of Oncology (3)
  6. Cancer Science (3)

More Publications

Publishers
  1. Elsevier Inc. (25)
  2. Oxford University Press (12)
  3. American Society of Clinical Oncology (11)
  4. Elsevier Science, Inc. (8)
  5. Nature Publishing Group (8)
  6. Wiley Blackwell (7)

More Publishers

Results (123)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia
    Journal Article

    Kreitman, R. J.; Tallman, M. S.; Robak, T.; Coutre, S.; Wilson, W. H.; Stetler-Stevenson, M.; FitzGerald, D. J.; Lechleider, R.; Pastan, I.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401
    Journal Article

    Kelly, W. K.; Halabi, S.; Carducci, M.; George, D.; Mahoney, J. F.; Stadler, W. M.; Morris, M.; Kantoff, P.; Monk, J. P.; Kaplan, E.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Journal Article

    Aghajanian, C.; Blank, S. V.; Goff, B. A.; Judson, P. L.; Teneriello, M. G.; Husain, A.; Sovak, M. A.; Yi, J.; Nycum, L. R.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma
    Journal Article

    Kindler, H. L.; Karrison, T. G.; Gandara, D. R.; Lu, C.; Krug, L. M.; Stevenson, J. P.; Jänne, P. A.; Quinn, D. I.; Koczywas, M. N.; Brahmer, J. R.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Bevacizumab for the treatment of high-grade glioma
    Journal Article

    Khasraw, M.; Simeonovic, M.; Grommes, C.
    Expert Opinion on Biological Therapy (2012)

    Fulltext@MSK | Save
  • Gastroenteropancreatic neuroendocrine tumors: Update on therapeutics
    Journal Article

    Ganetsky, A.; Bhatt, V.
    Annals of Pharmacotherapy (2012)

    Fulltext@MSK | Save
  • Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
    Journal Article

    Yang, J. C. H.; Shih, J. Y.; Su, W. C.; Hsia, T. C.; Tsai, C. M.; Ou, S. H. I.; Yu, C. J.; Chang, G. C.; Ho, C. L.; Sequist, L. V.; more...
    Lancet Oncology (2012)

    Fulltext@MSK | Save
  • Maximizing clinical outcomes with axitinib therapy in advanced renal cell carcinoma through proactive side-effect management
    Journal Article

    Wood, L. S.; Gornell, S.; Rini, B. I.
    Community Oncology (2012)

    Fulltext@MSK | Save
  • Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors
    Journal Article

    Chung, K. Y.; Saito, K.; Zergebel, C.; Hollywood, E.; Segal, M.; Saltz, L. B.
    Oncology (2011)

    Fulltext@MSK | Save
  • A phase i trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York cancer consortium trial NCI 6981
    Journal Article

    Tagawa, S. T.; Milowsky, M. I.; Jeske, S.; Mazumdar, M.; Kung, S.; Sung, M.; Lehrer, D.; Matulich, D.; Selzer, J.; Wright, J. J.; more...
    American Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save